- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 -  - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today rep ...